The aim of this registry is to provide information, in day-to-day practice, on Plerixafor prescription modalities in France, over a 13-month period in order to address the health authorities' request.
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
The characteristics of the patients who received treatment
Timeframe: 13 months
Dosage of treatment
Timeframe: 13 months
Number of CD34+ cells collected following treatment
Timeframe: 13 months
Number of patients with the existence of one or more predictive factors of poor mobilisation
Timeframe: 13 months
Duration of treatment
Timeframe: 13 months
Associated treatments
Timeframe: 13 months